Good Clinical Practice Compliance

Pharmaceutical Regulatory & Compliance Congress October 21, 2010 Greg Levine



Agenda?

• GCP compliance "rules"

- What is the law?
- What other (non-binding) standards apply?
- What are the unwritten expectations?
- Factors are affecting the current environment
- Enforcement changes
- What's next?

• FFDCA § 505(i)

- Authorizes FDA to promulgate regulations for exempting investigational new drugs from NDA approval requirement
- FDA Regulations
 - 21 C.F.R. Part 312, Subpart D (Duties of Sponsors, Investigators)
 - 21 C.F.R. Part 50 (Informed Consent)
 - 21 C.F.R. Part 56 (Institutional Review Boards)
 - 21 C.F.R. Part 54 (Investigator Financial Disclosure)

• 21 C.F.R. § 312.50 (General Duties of Sponsors)

- Selecting qualified investigators
- Providing investigators with the information needed to conduct the investigation properly
- Ensuring proper monitoring of the investigation
- Ensuring that the investigation is conducted in accordance with the protocol contained in the IND
- Maintaining an effective IND with respect to all investigations
- Ensuring that FDA and all participating investigators are promptly informed of significant new adverse effects or risks

- Specific Sponsor Obligations
 - Drug accountability and disposition
 - Obtaining information from the investigator (Form 1572)
 - Clinical protocol
 - Financial disclosure information (Part 54)
 - Selecting monitors
 - Investigator Brochure
 - Secure compliance from or terminate noncompliant investigators
 - Halting study in case of unreasonable risk to subjects
 - Recordkeeping and record retention
 - FDA inspection access
- IND safety reports (21 C.F.R. § 312.32)

- Non-IND studies: conditions of FDA acceptance to support an IND or marketing application
 - Well-designed and well-conducted
 - Conducted in accordance with good clinical practice (GCP)
 - FDA able to validate the data through an onsite inspection if necessary
 - Record retention

What other standards apply?

• FDA Non-Binding Guidance

- Safety Reporting Requirements for INDs and BA/BE Studies (Draft)(2010)
- IRB Continuing Review After Clinical Investigation Approval (Draft)(2010)
- Adverse Event Reporting to IRBs Improving Human Subject Protection (2009)
- CGMP for Phase 1 Investigational Drugs (2008)
- Establishment and Operation of Clinical Trial Data Monitoring Committees (2006)
- Using a Centralized IRB Review Process in Multicenter Clinical Trials (2006)
- Use of Clinical Holds Following Clinical Investigator Misconduct (2004)
- INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and Controls Data (2003)
- Financial Disclosure by Clinical Investigators (2001)
- Computerized Systems Used in Clinical Trials (1999)
- ICH E6 Good Clinical Practice: Consolidated Guidance (1996)
- Guideline for the Monitoring of Clinical Investigators (1988)

What other standards apply?

- FDA Non-Binding Guidance: Topical Information Sheets
 - Frequently Asked Questions Statement of Investigator (Form FDA 1572)(2010)
 - Data Retention When Study Subjects Withdraw from FDA-Regulated Clinical Trials (2008)
 - Waiver of IRB Requirements for Drug and Biological Product Studies (2006)
 - Acceptance of Foreign Clinical Studies (2001)
 - Charging for investigational products (1998)
 - Recruiting study subjects (1998)
 - Non-local IRB review (1998)
 - Payment to research subjects (1998)
 - Sponsor-Investigator-IRB relationship (1998)
 - Guide to Informed Consent (1998)
 - Treatment Use of Investigational Drugs (1998)
 - Drug Study Designs (1998)
 - Evaluation of Gender Differences (1998)


What other standards apply?

- International Guidance
 - ICH E6 Good Clinical Practice: Consolidated Guidance (1996)
 - Declaration of Helsinki

 Council for International Organizations of Medical Sciences (CIOMS) International Ethics Guidelines for Biomedical Research Involving Human Subjects

What does FDA expect?

- FDA public statements on "Quality Risk Management" in clinical trials
- Can't "inspect in" quality
- ISO quality management system involving a closed feedback loop



(http://www.iso.org/iso/iso_catalogue/management_standards/understand_the_basics.htm)

What does FDA expect?

- What should be covered in clinical trials QRM system?
 - Protocol design
 - Monitoring of protocol adherence
 - Data collection
 - Data analysis
- Implementation of QRM system
 - Implement an integrated system addressing key risks to data quality/integrity and subject protections
 - Use I.T. to detect irregularities (e.g., late data, data alterations)
 - Address human factors like staff qualifications, financial conflicts, manual data handling, and accountability

What does FDA expect?

- FDA now conducting inspections of sponsor's clinical trial "quality systems"
 - Select products in early, mid, and late development phases
 - Link with clinical investigator (site) inspections
 - "Require" submission of sponsor's "quality risk management system," including monitoring plan

What factors are affecting the current environment?

- OIG, "The FDA's Oversight of Clinical Trials" (2007)
- Congressional investigation of Ketek clinical trials (2008)
- OIG, "The FDA's Oversight of Clinical Investigators' Financial Information" (2009)
- GAO, "Oversight of Clinical Investigators: Action Needed to Improve Timeliness and Enhance Scope of FDA's Debarment and Disqualification Processes for Medical Product Investigators" (2009)
- GAO, "Human Subjects Research: Undercover Tests Show the IRB System is Vulnerable to Unethical Manipulation" (2009)
- OIG, "Challenges to FDA's Ability to Monitor and Inspect Foreign Clinical Trials" (2010)

FDA Enforcement

• Options to address regulatory violations (CPGM 7348.810)

- Warning and Untitled Letters
- Re-inspection
- Termination of an exemption (IND, IDE, INAD)
- Refusal to approve or license
- Withdrawal of approval (PMA, NDA, NADA)
- Implementation of the Application Integrity Policy
- Initiation of stock recovery
- Seizure of test articles
- Injunction
- Criminal prosecution
- Referral to other Federal, state, and local agencies

FDA Enforcement

Traditional approach

- Site selection based on highest enrollment or other qualitative risk perception
- Several sites per application
- If significant violations identified at some sites, FDA performed sensitivity analysis excluding those sites
- Data at other sites assumed to be reliable
- If data held up under sensitivity analysis, application could be approved

FDA Enforcement

• New approach

- Risk-based site selection using multifactor algorithm
- If first round of inspections shows significant violations, conduct second round
- Systems-based inspection of sponsor or CRO
- Request 3rd party audit of representative sites
- Compare 3rd party audit with sponsor monitoring reports and FDA inspections
- Assess whether violations were limited to FDA-inspected sites
- Hold sponsor and CRO accountable for inadequate monitoring and failure of quality systems by rejecting data, issuing Warning Letter, or conducting follow up inspections

What's next?

- Proposed Rule, "Reporting Information Regarding Falsification of Data" (Feb. 2010)
- Revised Compliance Policy Guide
- Guidance for Contract Research Organizations

Questions?

Greg Levine Ropes & Gray LLP 700 12th Street, N.W., Suite 900 Washington, D.C. 20005 Gregory.Levine@ropesgray.com 202-508-4831